qz
Novo Nordisk is partnering with OpenAI to speed up obesity drug discovery

The Danish drugmaker will integrate OpenAI's AI across research, manufacturing, and commercial operations, with full rollout by end of 2026 [...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

thenextweb
Novo Nordisk’s owner backs an Italian fund to grow drug startups beyond Denmark

Novo Holdings, the investment company that controls Novo Nordisk and holds the wealth of the Novo Nordisk Foundation, is backing a fund aimed at Italian drug startups, according to Bloomberg. The mov [...]

Match Score: 95.70

Destination
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]

Match Score: 88.43

Destination
Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump

Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.Read more... [...]

Match Score: 87.23

thenextweb
Novo Nordisk hands shelved Parkinson’s cell therapy to Zuckerberg-backed Cellular Intelligence

Novo will take an equity stake in Cellular Intelligence and is in line for future milestone payments and royalties. The startup plans to apply its AI platform to STEM-PD, a stem-cell-derived treatment [...]

Match Score: 87.23

thenextweb
Hacking group claims it breached Novo Nordisk and demanded $25m

A cyber-extortion group calling itself FulcrumSec said on Monday that it had stolen roughly 1.3 terabytes of data from Novo Nordisk, the Danish maker of the weight-loss drugs Wegovy and Ozempic, and h [...]

Match Score: 87.23

Destination
Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patients

Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half for even more patients that pay without insurance.Read more... [...]

Match Score: 69.96

venturebeat
Microsoft and OpenAI gut their exclusive deal, freeing OpenAI to sell on AWS and Google Cloud

Microsoft and OpenAI on Monday announced a sweeping overhaul of the partnership that has defined the commercial AI era, dismantling key pillars of exclusivity and revenue-sharing that bound the two co [...]

Match Score: 69.18

venturebeat
OpenAI deploys Cerebras chips for 15x faster code generation in first major move beyond Nvidia

OpenAI on Thursday launched GPT-5.3-Codex-Spark, a stripped-down coding model engineered for near-instantaneous response times, marking the company's first significant inference partnership outsi [...]

Match Score: 65.86

Destination
Hims & Hers strikes a deal with Novo Nordisk to sell Wegovy — and the stock soars 28%

Telehealth company Hims & Hers (HIMS) announced Tuesday that it will begin selling Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy.Read more... [...]

Match Score: 62.09